Table 2 Cancer characteristics at diagnosis for incident cases in the full population data for the MDC cohort and the cancer cases from the full nested case-control VIP cohort.
From: Prostate cancer polygenic risk score and prediction of lethal prostate cancer
Characteristica | MDC, N = 1576 | VIP, N = 2326 |
|---|---|---|
PSA at diagnosis | 10 (6, 23) | 10 (6, 20) |
Unknown | 299 | 825 |
Biopsy grade | ||
6 | 618 (43%) | 814 (53%) |
7 (3 + 4) | 248 (17%) | 0 (0%) |
7 (4 + 3) | 118 (8.2%) | 0 (0%) |
7 | 10 (0.7%) | 469 (31%) |
8 | 114 (7.9%) | 136 (8.9%) |
9 | 155 (11%) | 98 (6.4%) |
10 | 13 (0.9%) | 8 (0.5%) |
WHO Grade 1 | 84 (5.8%) | 0 (0%) |
WHO Grade 2 | 51 (3.5%) | 0 (0%) |
WHO Grade 3 | 27 (1.9%) | 0 (0%) |
Unknown | 138 | 801 |
Clinical T stage | ||
T0 | 21 (1.4%) | 3 (0.2%) |
T1 | 118 (8.1%) | 0 (0%) |
T1A | 37 (2.6%) | 45 (3.0%) |
T1B | 36 (2.5%) | 17 (1.1%) |
T1C | 423 (29%) | 725 (49%) |
T2 | 454 (31%) | 507 (34%) |
T3 | 320 (22%) | 178 (12%) |
T4 | 41 (2.8%) | 18 (1.2%) |
Unknown | 126 | 833 |
Clinical N stage | ||
N0 | 310 (21%) | 275 (18%) |
N1 | 34 (2.3%) | 25 (1.6%) |
Nx | 1106 (76%) | 1227 (80%) |
Unknown | 126 | 799 |
Clinical M stage | ||
M0 | 763 (53%) | 694 (45%) |
M1 | 125 (8.6%) | 125 (8.2%) |
Mx | 562 (39%) | 708 (46%) |
Unknown | 126 | 799 |
Metastatic at diagnosis | ||
No | 115 (7.3%) | 695 (30%) |
Yes | 95 (6.0%) | 125 (5.4%) |
Unknown | 1266 (87%) | 1506 (65%) |
Distant metastasis | – | 296 |
Unknown | 1576 | 0 |
Prostate cancer death | 288 | 168 |
